en · de · es · fr · pt
aod-9604-notes.peptides6088.com › Data › Regulatory And Analytical Context — Practical Notes

Regulatory And Analytical Context — Practical Notes

By Editorial Desk · published 2025-09-15 · last reviewed 2025-11-01 · Data

storage stability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Measurement and Storage Practices

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineStatus varies by country; prohibited in sport.
Common storage temperature2–8 °C for lyophilized powderProtect from light and moisture; follow supplier instructions.
Typical analytical methodLC-MS/MSUsed for identification and quantification in biological samples.
Purity assessmentHPLC and mass spectrometryReverse-phase HPLC is common for peptide purity.
Common synonymsAOD9604; hGH 176-191 fragmentNaming conventions differ across studies.

Identity and Research Origin

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Related pages on this site

Handling, Analysis, and Quality Control

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Background and Development History

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Mechanism And Metabolic Effects

A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.

Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

Notes from published material

A Study published by Altus Group indicates that 383 pubs closed in England during the first six months of 2023, including 46 in London. 9 October – Medway Council in Kent cancels its 2023 Christmas lights due to what it describes as a "challenging financial situation". 11 October – South Yorkshire Police says it is making "ongoing" inquiries after video footage emerged of a man climbing onto the roof of Sheffield Town Hall to replace an Israeli flag with a Palestinian one. An Independent Monitoring Board report into Wandsworth Prison has concluded that the prison is "unsafe and inhumane"; the report was prepared before the escape of Daniel Khalife in September. 12 October – Following reports that some student societies have been distributing leaflets in support of Hamas, education ministers Gillian Keegan and Robert Halfon have written to university vice chancellors in England urging them to "act swiftly and decisively against any threats" to students' safety and welfare. The number of people waiting for planned NHS treatment in England rises to 7.75 million. 13 October – Three Jewish schools in north London have closed for the day amid safety concerns for their students because of the ongoing conflict between Israel and Hamas. Police have detailed a 22-year-old woman on suspicion of supporting Hamas, which is a prescribed terrorist organisation in the UK, following a speech given at a protest in Brighton on 8 October.

==== Background ==== It is surprising to note that In 1980, there was no single chiral stationary phase available in the market for performing chiral chromatography. However, In late 1980s the subject of enantioselective chromatography attracted growing interest, particularly under the drive of the institution of Okamoto in Japan, the teams of Pirkle, and Armstrong in the US, Schurig and König in Germany, Lindner in Austria, and Francotte in Switzerland . The Polysaccharides, amylose and cellulose, form the most abundant chiral polymers on earth. These naturally occurring polysaccharides form basis for an important class of chiral selectors.

After the U.S. atomic bombs were dropped on Hiroshima and Nagasaki on August 6 and 9, 1945, an additional 130,000 people - in addition to the 100,000 immediate victims - died from the effects of radiation by the end of 1945. Some experienced the so-called walking ghost phase, an acute radiation sickness caused by a high equivalent dose of 6 to 20 Sievert after a lethal whole-body dose. The phase describes the period of apparent recovery of a patient between the onset of the first massive symptoms and the inevitable death. In the years that followed, a number of deaths from radiation-induced diseases were added. In Japan, the radiation-damaged survivors are called hibakusha (Japanese: 被爆者, lit. ''Explosion victim'') and are conservatively estimated to number about 100,000.

== Applications == Mass cytometry has research applications in medical fields including immunology, hematology, and oncology. It has been used in studies of hematopoiesis, cell cycle, cytokine expression, and differential signaling responses. MC has been used in various research fields, such as cancer biology, immunology, and neuroscience, to provide a more comprehensive understanding of tissue architecture and cellular interactions.

Cash inflows and outflows are the money that is put into, or received from, the property including the original purchase cost and sale revenue over the entire life of the investment. An example of this sort of investment is a real estate fund. Cash inflows include the following:

Sources: en.wikipedia.org

Further detail

Kidnapping for extortion and political purposes Simple kidnapping According to data from the Directorate of Justice and Security of the DNP, this phenomenon shows an increasing trend. With respect to the costs of sequestration, the sources suggest an increasing behavior between 1996 and 2003, such that "the average annual growth rate is 9.3%, the highest rate is observed in 1998 (46.2%), and in 2000 (37.2%) year in which the number of kidnappings also it is significantly high [...] reaching its peak in the year 2000 with 1,938 cases." From then on, the trend decreases, except for a peak in 2002 with 1,542 cases, until reaching 350 kidnappings in 2005 (the lowest figure since 1996). Within these costs, 64.4% are direct, representing US$167.4 million. 35.6% of the remaining costs are indirect, and represent US$92.7 million. In 2004, the costs of sequestration were reduced to $109,519 million, representing 0.27% of GDP in 2003.

== External links == Lipoprotein(a) at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P08519 (Apolipoprotein(a)) at the PDBe-KB.

== Quadrupole time-of-flight == Quadrupole time-of-flight mass spectrometry (QToF-MS) has a similar configuration to a tandem mass spectrometer with a mass-resolving quadrupole and collision cell hexapole, but instead of a second mass-resolving quadrupole, a time-of-flight mass analyzer is used. Both quadrupoles can operate in RF mode only to allow all ions to pass through to the mass analyzer with minimal fragmentation. To increase spectral detail, the system takes advantage of collision-induced dissociation. Once the ions reach the flight tube, the ion pulser sends them upwards towards the reflectron and back down into the detector. Since the ion pulser transfers the same kinetic energy to all molecules, the flight time is dictated by the mass of the analyte. QToF is capable of measuring mass to the 4th decimal place and is frequently used for pharmaceutical and toxicological analysis as a screening method for drug analogues. Identification is done by collection of the mass spectrum and comparison to tandem mass spectrum libraries.

=== Mechanism of action === Elbasvir targets the NS5A protein, which effectively prevents the transcription of the HCV RNA and also prevents virion assembly. "Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype." Grazoprevir is an protease inhibitor targeting HCV NS3/4A serine protease. Effectively grazoprevir prevents cleavage of the necessary polyproteins for replication.

NNC9204-1706 or NN9423 is a GLP-1/GIP/glucagon receptor triple agonist developed by Novo Nordisk. It was evaluated in a clinical trial; adverse effects such as "dose-dependent increases in heart rate and reductions in reticulocyte count, increases in markers of inflammation and hepatic disturbances, and impaired glucose tolerance at the highest dosages" meant that the drug was declared to have an inadequate safety profile and discontinued.

Sources: en.wikipedia.org

Supporting material

An expanded bed chromatographic adsorption (EBA) column for a biochemical separation process comprises a pressure equalization liquid distributor having a self-cleaning function below a porous blocking sieve plate at the bottom of the expanded bed, an upper part nozzle assembly having a backflush cleaning function at the top of the expanded bed, a better distribution of the feedstock liquor added into the expanded bed ensuring that the fluid passed through the expanded bed layer displays a state of piston flow. The expanded bed layer displays a state of piston flow. The expanded bed chromatographic separation column has advantages of increasing the separation efficiency of the expanded bed. Expanded-bed adsorption (EBA) chromatography is a convenient and effective technique for the capture of proteins directly from unclarified crude sample. In EBA chromatography, the settled bed is first expanded by upward flow of equilibration buffer. The crude feed, which is a mixture of soluble proteins, contaminants, cells, and cell debris, is then passed upward through the expanded bed. Target proteins are captured on the adsorbent, while particulates and contaminants pass through. A change to elution buffer while maintaining upward flow results in desorption of the target protein in expanded-bed mode. Alternatively, if the flow is reversed, the adsorbed particles will quickly settle and the proteins can be desorbed by an elution buffer. The mode used for elution (expanded-bed versus settled-bed) depends on the characteristics of the feed.

=== Magnetic and Magnetoelectric nanoparticles === In contrast to the above mechanisms, a delivery with magnetic fields does not strongly depend on the biochemistry of the brain. In this case, nanoparticles are literally pulled across the BBB via application of a magnetic field gradient. The nanoparticles can be pulled in as well as removed from the brain merely by controlling the direction of the gradient. For the approach to work, the nanoparticles must have a non-zero magnetic moment and have a diameter of less than 50 nm. Both magnetic and magnetoelectric nanoparticles (MENs) satisfy the requirements. However, it is only the MENs which display a non-zero magnetoelectric (ME) effect. Due to the ME effect, MENs can provide a direct access to local intrinsic electric fields at the nanoscale to enable a two-way communication with the neural network at the single-neuron level. MENs, proposed by the research group of Professor Sakhrat Khizroev at Florida International University (FIU), have been used for targeted drug delivery and externally controlled release across the BBB to treat HIV and brain tumors, as well as to wirelessly stimulate neurons deep in the brain for treatment of neurodegenerative diseases such as Parkinson's Disease and others.

Developing isotopic reference materials specifically for clumped isotope analysis remains an ongoing goal of this rapidly developing field and was a major discussion topic during the 6th International Clumped Isotopes Workshop in 2017. It is possible that researchers in the future will measure clumped isotope ratios against internationally distributed reference materials, similar to the current method of measuring the bulk isotope composition of unknown samples.

=== Legal status === The FDA granted the application for pegcetacoplan orphan drug designation. In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aspaveli, intended for the treatment of adults with paroxysmal nocturnal hemoglobinuria. The applicant for this medicinal product is Swedish Orphan Biovitrum AB (publ). Pegcetacoplan was approved for the treatment of paroxysmal nocturnal hemoglobinuria in the European Union in December 2021. FDA approved Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration (ARMD) in February 2023. In June 2024, the CHMP recommended the refusal of a marketing authorization for Syfovre, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration. The manufacturer requested a re-examination in July 2024. In September 2024, the CHMP continued to refuse a marketing authorization after a re-examination.

== Facilities == The Fat Duck has 14 tables and can seat 42 diners. It has a high proportion of chefs working, 42, equating to one chef per diner. Much of the menu is developed by experimentation: for example, the egg and bacon ice cream came about following Blumenthal investigating the principles of "flavour encapsulation". A research laboratory where Blumenthal and his team develop dishes is two doors away opposite the Hind's Head pub, which he also owns. It was where the majority of the laboratory scenes for the television series Heston Blumenthal: In Search of Perfection were filmed. The lab equipment includes a centrifuge which is used to make chocolate wine, and a vacuum oven. The restaurant takes reservations up to two months in advance, and in 2011 it was receiving some 30,000 calls for reservations per day, although that figure also included people who could not get through and were redialling.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Why is it banned in sports?

The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.

How is AOD-9604 detected?

Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

Network